A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases

Recent advancement in the understanding of the pathophysiology of inflammatory bowel disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 inhibitor, and ustekinumab, an IL 12/23 p40 inhibitor, have provided the much‐awaited out‐of‐class alternatives for patients who ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Hang Hock, Chan, Pak Wo, Chuah, Sai Wei, Schwender, Brian J, Kong, San Choon, Ling, Khoon Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2018
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207060/
https://www.ncbi.nlm.nih.gov/pubmed/30483594
http://dx.doi.org/10.1002/jgh3.12065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207060/
https://www.ncbi.nlm.nih.gov/pubmed/30483594
http://dx.doi.org/10.1002/jgh3.12065

Ejemplares similares